...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Infectious Diseases >Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.
【24h】

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.

机译：甲型H5流感亚单位疫苗的安全性和免疫原性：疫苗接种方案和抗原变异体的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The current US national stockpile of influenza H5 vaccine was produced using the antigen from the strain A/Vietnam/1203/2004 (a clade 1 H5 virus). Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus). METHODS: The influence of schedule on the antibody response to 2 doses of H5 vaccines (one a clade 1 hemagglutinin protein [HA] vaccine and one a clade 2 HA vaccine) containing 90 mug of antigen was evaluated in healthy adults 18-49 years of age. RESULTS: Two doses of vaccine were required to induce antibody titers >/= 1:10 in most subjects. Accelerated schedules were immunogenic, and antibody developed after vaccinations on days 0 and 7, 0 and 14, and 0 and 28, with the day 0 and 7 schedule inducing lower titers than those induced with the other schedules. With mixed vaccine schedules of clade 1 followed by clade 2 vaccine administration, the first vaccination primed for a heterologous boost. The heterologous response was improved when the second vaccination was given 6 months after the first, compared with the response when the second vaccination was given after an interval of 1 month. CONCLUSIONS: An accelerated vaccine schedule of injections administered at days 0 and 14 was as immunogenic as a vaccine schedule of injections at days 0 and 28, but both schedules were inferior to a vaccine schedule of injections administered at 0 and 6 months for priming for heterologous vaccine boosting. Clinical Trial Registry Number: NCT00703053.
机译：背景：目前美国的国家H5流感疫苗库存是使用A / Vietnam / 1203/2004株的抗原（进化枝1 H5病毒）生产的。最近的H5疾病是由抗原性不同的H5病毒引起的，包括A / Indonesia / 05/2005（进化枝2 H5病毒）。方法：在18岁至49岁的健康成年人中，评估了日程对含90杯抗原的2剂H5疫苗（一种进化枝1血凝素蛋白[HA]疫苗和一种进化枝2 HA疫苗）的抗体反应的影响。年龄。结果：在大多数受试者中，需要两剂疫苗才能诱导抗体滴度> / = 1:10。加速的时间表具有免疫原性，在第0天和第7天，0和14天以及0和28天接种疫苗后产生抗体，而第0天和第7天的诱导抗体滴度低于其他时间表。在进行进化枝1的混合疫苗计划后，再进行进化枝2的疫苗管理，第一次疫苗接种会引发异源加强免疫。与间隔1个月后进行第二次疫苗接种相比，第一次接种后6个月进行第二次疫苗接种能够改善异源反应。结论：在第0和14天注射的加速疫苗时间表与在第0和28天注射的疫苗时间表一样具有免疫原性，但两种时间表均次于在0和6个月用于异源引发的注射疫苗时间表加强疫苗。临床试验注册号：NCT00703053。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号